NDAORALTABLETPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
16
Data completeness
6/8 — Strong
Priority Review
ARAVA (leflunomide) by Sanofi. Approved for antirheumatic agent [epc]. First approved in 1998.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARAVA (leflunomide) is an oral small-molecule antirheumatic agent approved in 1998 for the treatment of rheumatoid arthritis. It works through immunomodulation to reduce inflammation and joint damage in RA patients. The drug is administered as an oral tablet, making it accessible for chronic disease management.
$0.001BPart D
LOE ApproachingDeclining
Declining Part D spending and limited claims indicate a shrinking market; teams are likely focused on managed care retention rather than growth expansion.
Mechanism of Action
Pharmacologic Class:
Antirheumatic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Started May 2025
302 enrolled
Rheumatoid ArthritisPsoriatic Arthritis
A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks
Started Feb 2025
200 enrolled
Paravalvular Leak Device (PLD)
Bioequivalence Study of Generic Leflunomide 20 mg Film-coated Tablets and Reference Product Under Fasting Conditions
Started Apr 2024
48 enrolled
Healthy Volunteer
Leflunomide Treatment for IgG4-RD
Started Jul 2018
70 enrolled
Autoimmune Disease
Laparoscopic Three-dimensional Versus Two-dimensional Sacral Colpopexy and Paravaginal Repair
Started Dec 2014
194 enrolled
Pelvic Organ ProlapseCystocele
Worked on ARAVA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.